Bioceres Crop Solutions Corp. Q4 2026 Earnings Recap

Investors focused on Bioceres’ 18% full-year revenue decline and continued earnings pressure, sending the stock down 9.9% after results. While fourth-quarter revenue stabilized and cost cuts restored modestly positive EBITDA, reported gross profit fell and management did not provide a clear near-term recovery catalyst.

Key Takeaways

• Full-year continuing-operations revenue declined 18% to approximately $238 million, with weakness concentrated in international operations, crop protection, and the reconfigured seed business.
• Fourth-quarter revenue was broadly flat at $55.9 million versus $55.4 million a year earlier; crop nutrition grew 36%, led by microbeaded fertilizer, but this was offset by lower crop protection and seed revenue.
• Fourth-quarter reported gross profit fell 6% to $12.7 million, with gross margin of 22.8%, including an approximately $4 million nonrecurring inventory-obsolescence adjustment.
• Cost reductions improved fourth-quarter adjusted EBITDA by roughly $10 million year over year, from negative $9.6 million to positive $0.6 million; full-year adjusted EBITDA nevertheless declined to $25.5 million from $28.9 million.
• Management cited improving profitability in microbeaded fertilizer, adjuvants, and seed-treatment packs, but inoculants and remaining seed operations continued to weigh on reported performance.